In our study, overexpression of ADORA2A-AS1 in CML suggests that it may be used as a marker of diagnosis and prognosis, but its clinical application needs to be verified in more clinical samples. This evidence concerns the gene ADORA2A and chronic myelogenous leukemia, BCR-ABL1 positive.